Skip to main content
. 2018 Nov 3;8(4):76. doi: 10.3390/metabo8040076

Figure 1.

Figure 1

Upper Figure: Pilot study of plasma levels (100 μL) of VLCDCA 28:4 in controls (Con; N = 15) and patients with kidney (Kid; N = 7), breast (BR; N = 7), colorectal (CRC; N = 9), or glioblastoma multiforme (GBM; N = 12) cancers. Lower Figure: Validation study of plasma levels (100 μL) of VLCDCA 28:4 in controls (Con; N = 16) and patients with colorectal (CRC; N = 26), kidney (Kid; N = 9), or pancreatic (Pan; N = 45) cancers. R represents ratio of the peak area of endogenous VLCDCA 28:4 to the peak area of 1 nanomole of [2H28]DCA 16:0. *, p < 0.01 (t-test).